5%) progressed to the stage of compensated cirrhosis and a single patient developed HCC; in the 47 cirrhotics
at presentation, HCC occurred in 14 (30%) and
events of liver failure in 5 (11%). The 5 and 10- year survival free of events was, respectively, 90.1% and 77% for patients with chronic hepatitis, and 71% and 43.7% for cirrhotics.
Conclusions: The rationale beyond continuous NUCs administration is to attain and maintain viral clearance.